Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.50
- Piotroski Score 4.00
- Grade Buy
- Symbol (GHSI)
- Company Guardion Health Sciences, Inc.
- Price $5.69
- Changes Percentage (-1.56%)
- Change -$0.09
- Day Low $5.51
- Day High $5.81
- Year High $18.00
Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.
- Last Earnings 08/21/2024
- Ex-Dividend for 5/16 Dividend 09/24/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.01
- High Stock Price Target $0.01
- Low Stock Price Target $0.01
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.01
- Trailing P/E Ratio -2.47
- Forward P/E Ratio -2.47
- P/E Growth -2.47
- Net Income $158,033
